<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36810294</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A fragment of type VI collagen alpha-6 chain is elevated in serum from patients with atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus and melanoma.</ArticleTitle><Pagination><StartPage>3056</StartPage><MedlinePgn>3056</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3056</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-28746-2</ELocationID><Abstract><AbstractText>Extracellular matrix (ECM) remodeling of the skin is a continuous process necessary for maintaining tissue homeostasis. Type VI collagen (COL6) is characterized as a beaded filament, located in the dermal ECM, where COL6-&#x3b1;6-chain has been demonstrated upregulated in atopic dermatitis. The aim of this study was to develop and validate a competitive ELISA, targeting the N-terminal of COL6-&#x3b1;6-chain, named C6A6, and evaluate its associations with the dermatological condition's atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus, systemic sclerosis, urticaria, vitiligo, and cutaneous malignant melanoma in comparison, to healthy controls. A monoclonal antibody was raised and employed in an ELISA assay. The assay was developed, technically validated, and evaluated in two independent patient cohorts. Cohort 1 showed C6A6 was significantly elevated in patients with atopic dermatitis (p&#x2009;&lt;&#x2009;0.0001), psoriasis (p&#x2009;&lt;&#x2009;0.0001), hidradenitis suppurativa (p&#x2009;=&#x2009;0.0095), systemic lupus erythematosus (p&#x2009;=&#x2009;0.0032) and melanoma (p&#x2009;&lt;&#x2009;0.0001) compared to healthy donors. Cohort 2 confirmed C6A6 being upregulated in atopic dermatitis compared to healthy controls (p&#x2009;&lt;&#x2009;0.0001), but also associated with disease severity (SCORAD, p&#x2009;=&#x2009;0.046) and lowered in patients receiving calcineurin inhibitors (p&#x2009;=&#x2009;0.014). These findings are hypothesis generating, and the utility of the C6A6 biomarker for disease severity and treatment response needs to be validated in larger cohorts and longitudinal studies.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holm Nielsen</LastName><ForeName>Signe</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunoscience, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark. shn@nordicbio.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Port</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Immunoscience, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller Hausgaard</LastName><ForeName>Cecilie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunoscience, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Jesper Gr&#xf8;nlund</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thyssen</LastName><ForeName>Jacob P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groen</LastName><ForeName>Solveig Skovlund</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Immunoscience, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karsdal</LastName><ForeName>Morten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunoscience, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Valdemar Wendelboe</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egeberg</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bay-Jensen</LastName><ForeName>Anne-Christine</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Immunoscience, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Simon Francis</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024142">Collagen Type VI</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003876" MajorTopicYN="Y">Dermatitis, Atopic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024142" MajorTopicYN="N">Collagen Type VI</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017497" MajorTopicYN="Y">Hidradenitis Suppurativa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011565" MajorTopicYN="Y">Psoriasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>SHN, HP, CMH, MK, and ACBJ are full-time employees at Nordic Bioscience A/S. Nord 9. Nordic Bioscience is a privately-owned, small&#x2013;medium-size enterprise (SME) partly focused on developing biomarkers. None of the authors received fees, bonuses, or other benefits for the work described in the manuscript. SHN, MAK, and ACBJ hold stocks in Nordic Bioscience A/S. JGH, JPT, SSG, VWN, AE and SFT have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>14</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36810294</ArticleId><ArticleId IdType="pmc">PMC9945456</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-28746-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-28746-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Simon D, Aeberhard C, Erdemoglu Y, Simon HU. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy. 2014;69:125&#x2013;131. doi: 10.1111/all.12351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.12351</ArticleId><ArticleId IdType="pubmed">24372156</ArticleId></ArticleIdList></Reference><Reference><Citation>Dengjel J, Bruckner-Tuderman L, Nystr&#xf6;m A. Skin proteomics&#x2013;analysis of the extracellular matrix in health and disease. Expert Rev. Proteomics. 2020;17:377&#x2013;391. doi: 10.1080/14789450.2020.1773261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2020.1773261</ArticleId><ArticleId IdType="pubmed">32552150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch MD, Watt FM. Fibroblast heterogeneity: Implications for human disease. J. Clin. Invest. 2018;128:26&#x2013;35. doi: 10.1172/JCI93555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI93555</ArticleId><ArticleId IdType="pmc">PMC5749540</ArticleId><ArticleId IdType="pubmed">29293096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J. Cell Sci. 2015;128:3525&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">26377767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner MFMG, Theodoro TR, Filho CDASM, Oyafuso LKM, Pinhal MAS. Extracellular matrix alterations in the skin of patients affected by psoriasis. BMC Mol. Cell Biol. 2021;22:1. doi: 10.1186/s12860-021-00395-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12860-021-00395-1</ArticleId><ArticleId IdType="pmc">PMC8555298</ArticleId><ArticleId IdType="pubmed">34715781</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm Nielsen S, et al. A fragment of collagen type VI alpha-3 chain is elevated in serum from patients with gastrointestinal disorders. Sci. Rep. 2020;10:5910. doi: 10.1038/s41598-020-62474-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62474-1</ArticleId><ArticleId IdType="pmc">PMC7125205</ArticleId><ArticleId IdType="pubmed">32245981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald J, Holden P, Hansen U. The expanded collagen VI family: New chains and new questions. Connect. Tissue Res. 2013;54:345&#x2013;350. doi: 10.3109/03008207.2013.822865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03008207.2013.822865</ArticleId><ArticleId IdType="pmc">PMC5248970</ArticleId><ArticleId IdType="pubmed">23869615</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgios T, et al. Type VI collagen regulates dermal matrix assembly and fibroblast motility. J. Invest. Dermatol. 2016;136:74&#x2013;83. doi: 10.1038/JID.2015.352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/JID.2015.352</ArticleId><ArticleId IdType="pubmed">26763426</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrota R, et al. Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatol. 2021;3:e175&#x2013;e184. doi: 10.1016/S2665-9913(20)30385-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30385-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung HJ, et al. The role of collagen VI &#x3b1;6 chain gene in atopic dermatitis. Ann. Dermatol. 2022;34:46&#x2013;54. doi: 10.5021/ad.2022.34.1.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.5021/ad.2022.34.1.46</ArticleId><ArticleId IdType="pmc">PMC8831303</ArticleId><ArticleId IdType="pubmed">35221595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh D, et al. Multiple transcriptome data analysis reveals biologically relevant atopic dermatitis signature genes and pathways. PLoS ONE. 2015;10:1&#x2013;23. doi: 10.1371/journal.pone.0144316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0144316</ArticleId><ArticleId IdType="pmc">PMC4696650</ArticleId><ArticleId IdType="pubmed">26717000</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo, W. Il et al. Identification of novel candidate variants including COL6A6 polymorphisms in early-onset atopic dermatitis using whole-exome sequencing. BMC Med. Genet.18, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5270287</ArticleId><ArticleId IdType="pubmed">28125976</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki S, Fujiwara S, Shinkai H, Ooshima A. Human type VI collagen: Purification from human subcutaneous fat tissue and an immunohistochemical study of morphea and systemic sclerosis. J. Dermatol. 1995;22:480&#x2013;485. doi: 10.1111/j.1346-8138.1995.tb03428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1346-8138.1995.tb03428.x</ArticleId><ArticleId IdType="pubmed">7560437</ArticleId></ArticleIdList></Reference><Reference><Citation>Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 1977;3:231&#x2013;236. doi: 10.1007/BF01551818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01551818</ArticleId><ArticleId IdType="pubmed">605383</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm JG, Agner T, Clausen ML, Thomsen SF. Determinants of disease severity among patients with atopic dermatitis: Association with components of the atopic march. Arch. Dermatol. Res. 2019;311:173&#x2013;182. doi: 10.1007/s00403-019-01895-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00403-019-01895-z</ArticleId><ArticleId IdType="pubmed">30770978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamand&#xe9; SR, Bateman JF. Collagen VI disorders: Insights on form and function in the extracellular matrix and beyond. Matrix Biol. 2018;71&#x2013;72:348&#x2013;367. doi: 10.1016/j.matbio.2017.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2017.12.008</ArticleId><ArticleId IdType="pubmed">29277723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lettmann S, et al. Col6a1 null mice as a model to study skin phenotypes in patients with collagen VI related myopathies: Expression of classical and novel collagen vi variants during wound healing. PLoS ONE. 2014;9:e105686. doi: 10.1371/journal.pone.0105686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105686</ArticleId><ArticleId IdType="pmc">PMC4144880</ArticleId><ArticleId IdType="pubmed">25158062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J. Cutan. Med. Surg. 2014;18:8&#x2013;14. doi: 10.2310/7750.2013.13059.</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/7750.2013.13059</ArticleId><ArticleId IdType="pubmed">24377467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Adv. Dermatol. Allergol. Dermatologii Alergol. 2013;30:165. doi: 10.5114/pdia.2013.35619.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/pdia.2013.35619</ArticleId><ArticleId IdType="pmc">PMC3834721</ArticleId><ArticleId IdType="pubmed">24278069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int. J. Clin. Pract. 2005;59:969&#x2013;974. doi: 10.1111/j.1368-5031.2005.00587.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1368-5031.2005.00587.x</ArticleId><ArticleId IdType="pubmed">16033622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am. Acad. Dermatol. 2002;46:228&#x2013;241. doi: 10.1067/mjd.2002.120942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mjd.2002.120942</ArticleId><ArticleId IdType="pubmed">11807435</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>